Paper2479986
Vascular endothelial growth factor is a secreted angiogenic mitogen.
Leung DW and 4 others. Science, 1989. Cited by 4,354 papers, by iCite.
Cite this record
ConductScience Library. Vascular endothelial growth factor is a secreted angiogenic mitogen. Papers, record 2479986. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2479986
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Endothelium, Vascular | Major topic |
| Lymphokines | Major topic |
| Neovascularization, Pathologic | Major topic |
| Amino Acid Sequence | |
| Animals | |
| Base Sequence | |
| Blotting, Northern | |
| Cattle | |
| Cell Division | |
| Cloning, Molecular | |
| Gene Library | |
| Humans | |
| Molecular Sequence Data | |
| Sequence Homology, Nucleic Acid | |
| Vascular Endothelial Growth Factor A | |
| Vascular Endothelial Growth Factors |
Source PubMed
Cited by1,353
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4,354 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42920650 | Exploratory machine-learning analysis of bevacizumab exposure and circulating VEGF dynamics in patients with cancer. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42920650 | PubMed |
| 42818544 | Cap-Independent Translation Regulation of VEGF Using CRISPR-dCas13d. | bioRxiv | 2026 | https://conductscience.org/library/papers/42818544 | PubMed |
| 42792843 | The Molecular Basis and Biomarker Potential of the HIF-1α-VEGF-GLUT1 Hypoxia Axis in Laryngeal Squamous Cell Carcinoma. | Biomedicines | 2026 | https://conductscience.org/library/papers/42792843 | PubMed |
| 42738409 | The Immune Landscape of Chondrosarcoma: A Review of Tumor-Related Immune Cells. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738409 | PubMed |
| 42577617 | ETS transcription factor ELK3: Molecular insights and translational horizons in cancer (Review). | Oncol Lett | 2026 | https://conductscience.org/library/papers/42577617 | PubMed |
| 42465853 | Efficacy and safety of immune checkpoint inhibitors combined with anti-angiogenic agents for advanced cervical cancer: A systematic review and meta-analysis. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42465853 | PubMed |
| 42455955 | Mechanisms of VEGFR2 activation by VEGF, neuropilin, and heparin. | Sci Adv | 2026 | https://conductscience.org/library/papers/42455955 | PubMed |
| 42426779 | In vivo and in silico wound healing potential of Cannabis Sativa seed oil through inflammation mediators. | BMC Complement Med Ther | 2026 | https://conductscience.org/library/papers/42426779 | PubMed |
| 42386923 | Base editing-derived models of human WDR34 and WDR60 disease alleles replicate retrograde intraflagellar transport (IFT) and hedgehog signaling defects. | Commun Biol | 2026 | https://conductscience.org/library/papers/42386923 | PubMed |
| 42346144 | The Interplay of Splicing and Metabolism in Cancer. | Cells | 2026 | https://conductscience.org/library/papers/42346144 | PubMed |
| 42346131 | Angiogenic Gene Therapy for Lower Extremity Ischemia: Experimental Advances and Clinical Experience. | Cells | 2026 | https://conductscience.org/library/papers/42346131 | PubMed |
| 42165956 | Angiogenic Doping: Plausible Yet Difficult to Detect. | Sports Med | 2026 | https://conductscience.org/library/papers/42165956 | PubMed |
| 42165644 | Development of Miniprotein Binders to Inhibit VEGF-Induced Corneal Neovascularization. | Invest Ophthalmol Vis Sci | 2026 | https://conductscience.org/library/papers/42165644 | PubMed |
| 42156503 | Adipocytes influence choroidal neovascularization via PRDM16. | EMBO Mol Med | 2026 | https://conductscience.org/library/papers/42156503 | PubMed |
| 42068530 | ANRIL in Cardiovascular Diseases: Expression, Mechanism and Therapeutic Implications. | Cardiovasc Drugs Ther | 2026 | https://conductscience.org/library/papers/42068530 | PubMed |
| 42018104 | Efficacy and safety of second-line fluorouracil, leucovorin, and irinotecan plus ramucirumab according to prior first-line regimens in metastatic colorectal cancer: a multicenter retrospective study. | Int J Clin Oncol | 2026 | https://conductscience.org/library/papers/42018104 | PubMed |
| 42016824 | Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging for Predicting Immunotherapy Response in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. | Liver Cancer | 2026 | https://conductscience.org/library/papers/42016824 | PubMed |
| 42015870 | Aptamer-Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies. | Adv Healthc Mater | 2026 | https://conductscience.org/library/papers/42015870 | PubMed |
| 42014919 | Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study. | Commun Med (Lond) | 2026 | https://conductscience.org/library/papers/42014919 | PubMed |
| 42004816 | Advancements in targeted therapy for gastric cancer. | Ther Adv Gastroenterol | 2026 | https://conductscience.org/library/papers/42004816 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| VEGFA | 7422 | Swiss-Prot's references | https://conductscience.org/library/genes/7422 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2479986
GET https://conductscience.org/api/papers/v1/2479986/cited_by?page=2